Sex hormones and sarcopenia in older persons

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 1, 2013, Pages 3-13

  Maggio, Marcello ^a,b   Lauretani, Fulvio ^b   Ceda, Gian Paolo ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

DHEAS; older men; sarcopenia; testosterone

Indexed keywords

ANDROGEN; DUTASTERIDE; LGD 4033; PLACEBO; PRASTERONE SULFATE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SEX HORMONE; TESTOSTERONE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

AGED; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MALE; META ANALYSIS; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; PATIENT SELECTION; PHYSICAL DISABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

AGED; ANDROGENS; DEHYDROEPIANDROSTERONE SULFATE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERIATRIC ASSESSMENT; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MOTOR ACTIVITY; MUSCLE, SKELETAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOPENIA; TESTOSTERONE;

EID: 84871921465     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32835b6044     Document Type: Article

References (42)

1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensuson definition and diagnosis: report of the European WorkingGroup onSarcopenia in Older People. Age Ageing 2010; 39:412-423
2. Morley JE, Abbatecola AM, Argiles JM, et al. Society on Sarcopenia, Cachexiaand Wasting Disorders Trialist Workshop. Sarcopenia with limitedmobility: an international consensus. J Am Med Dir Assoc 2011; 12:403-409
3. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia,cachexia and precachexia: joint document elaborated by Special InterestGroups (SIG) 'cachexia-anorexia in chronic wasting diseases' and 'nutrition ingeriatrics'. Clin Nutr 2010; 29:154-159
4. Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int JEndocrinol 2012; 127362
5. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levelsof anabolic hormones and 6-year mortality in older men: the aging inthe Chianti Area (InCHIANTI) study. Arch Intern Med 2007; 167:2249-2254 (Pubitemid 350106746)
6. Maggio M, Cattabiani C, Lauretani F, et al. The concept of multiple hormonaldysregulation. Acta Biomed 2010; 81 (Suppl 1):19-29
7. Stewart CE, Pell JM. Point: Counterpoint: IGF is/is not the major physiologicalregulator of muscle mass. Point: IGF is the major physiological regulator ofmuscle mass. J Appl Physiol 2010; 108:1820-1821
8. Wagers AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration:current concepts and controversies in adult myogenesis. Cell 2005;122:659-667 (Pubitemid 41242632)
9. Serra C, Tangherlini F, Rudy S, et al. Testosterone improves the regenerationof old and young mouse skeletal muscle. J Gerontol A Biol Sci Med Sci 2012[Epub ahead of print]
10. Dubois V, Laurent M, Boonen S, et al. Androgens and skeletal muscle: cellularand molecular action mechanisms underlying the anabolic actions. Cell MolLife Sci 2012; 69:1651-1667
11. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacementon endogenous inflammatory cytokines and lipid profiles in hypogonadal men.J Clin Endocrinol Metab 2004; 89:3313-3318 (Pubitemid 38951897)
12. Grossmann MJ. Low testosterone in men with type 2 diabetes: significanceand treatment. J Clin Endocrinol Metab 2011; 96:2341-2353
13. Ferná ndez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverseeffects of testosterone therapy in adult men: a systematic review and metaanalysis.J Clin Endocrinol Metab 2010; 95:2560-2575
14. Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on musclestrength and physical function in older adults: a systematic review. J AmGeriatr Soc 2011; 59:997-1002
15. Kenny AM, Boxer RS, Kleppinger A, et al. Dehydroepiandrosterone (DHEA)improves muscle strength and physical function but not bone mineral densityin frail older women. J Am Geriatr Soc 2010; 58:1707-1714
16. Igwebuike A, Irving BA, Bigelow ML, et al. Lack of dehydroepiandrosteroneeffect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab 2008; 93:534-538 (Pubitemid 351240827)
17. Muller M, van den Beld AW, van der Schouw YT, et al. Effects of dehydroepiandrosteroneand atemestane supplementation on frailty in elderly men.J Clin Endocrinol Metab 2006; 91:3988-3991 (Pubitemid 44536874)
18. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA ortestosterone in elderly men. N Engl J Med 2006; 355:1647-1659 (Pubitemid 44583955)
19. Villareal DT, Holloszy JO. DHEA enhances effects of weight training onmuscle mass and strength in elderly women and men. Am J Physiol EndocrinolMetab 2006; 291:E1003-E1008
20. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, et al. Androgen treatmentand muscle strength in elderly men: a meta-analysis. J Am Geriatr Soc 2006;54:1666-1673 (Pubitemid 44665204)
21. Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone onbone and muscle in older men with low bioavailable testosterone levels, lowbone mass, and physical frailty. J Am Geriatr Soc 2010; 58:1134-1143
22. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone onmuscle strength, physical function, body composition, and quality of life inintermediate-frail and frail elderly men: a randomized, double-blind, placebocontrolledstudy. J Clin Endocrinol Metab 2010; 95:639-650
23. Travison TG, Basaria S, Storer TW, et al. Clinical meaningfulness of thechanges in muscle performance and physical function associated withtestosterone administration in older men with mobility limitation. J GerontolA Biol Sci Med Sci 2011; 66:1090-1099
24. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated withtestosterone administration. N Engl J Med 2010; 363:109-122
25. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascularrisk in men: a systematic review and meta-analysis of randomized placebocontrolledtrials. Mayo Clin Proc 2007; 82:29-39 (Pubitemid 46036319)
26. Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selectiveandrogen receptor modulators as anabolic therapies for chronic illness andaging. Nature Clin Pract Endocrinol Metab 2006; 2:146-159
27. Maggio M, Ceda GP, Lauretani F, et al. Gonadal status and physicalperformance in older men. Aging Male 2011; 14:42-47
28. Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASArecommendations: investigation, treatment and monitoring of late-onsethypogonadism in males. Aging Male 2009; 12:5-12
29. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms andmetabolic risks with serum testosterone in older men. J Clin Endocrinol Metab2006; 91:4335-4343 (Pubitemid 44833407)
30. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosteronesupplementation on functional mobility, cognition, and other parametersin older men: a randomized controlled trial. J Am Med Assoc 2008; 299:39-52
31. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism inmiddle-aged and elderly men. N Engl J Med 2010; 363:123-135
32. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men withandrogen deficiency syndromes: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab 2010; 95:2536-2559
33. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementationwith and without a dual 5(-reductase inhibitor on fat-free mass in men withsuppressed testosterone production: a randomized controlled trial. J Am MedAssoc 2012; 307:931-939
34. Sheffield-Moore M, Dillon EL, Casperson SL, et al. A randomized pilot study ofmonthly cycled testosterone replacement or continuous testosterone replacementversus placebo in older men. J Clin Endocrinol Metab 2011;96:E1831-E1837.Original pilot study that shows an interesting option to improve the safety oftestosterone treatment in older men and highlights the timing of intervention andthe onset of anabolic and anticatabolic mechanisms
35. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effectsof LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator,in healthy young men. J Gerontol A Biol Sci Med Sci 2012 [Epub aheadof print]
36. Dominguez LJ, Barbagallo M, Lauretani F, et al. Magnesium and muscleperformance in older persons: the InCHIANTI study. Am J Clin Nutr 2006;84:419-426 (Pubitemid 44699155)
37. Maggio M, Ceda GP, Lauretani F, et al. Magnesium and anabolic hormones inolder men. Int J Androl 2011; 34:e594-e600
38. Chapman IM, Visvanathan R, Hammond AJ, et al. Effect of testosterone and anutritional supplement, alone and in combination, on hospital admissions inundernourished older men and women. Am J Clin Nutr 2009; 89:880-889
39. Piantadosi C, Visvanathan R, Naganathan V, et al. The effect of testosteroneand a nutritional supplement on hospital admissions in under-nourished, olderpeople. BMC Geriatr 2011; 11:66
40. Basaria S, Bhasin S. Targeting the skeletal muscle-metabolism axis inprostate-cancer therapy. N Engl J Med 2012; 367:965-967
41. Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictorof mortality and major morbidity in elderly patients undergoing cardiac surgery.J Am Coll Cardiol 2010; 56:1668-1676
42. Maggio M, Nicolini F, Cattabiani C, et al. Effects of testosterone supplementationon clinical and rehabilitative outcomes in older men undergoing on-pumpCABG. Contemp Clin Trials 2012; 33:730-738